

PROJECT DIAMOND


Interventional Psychiatry Platform
SPRAVATO® · TMS · Ketamine Therapy · Medication Management · HRT

Company Overview

Project Diamond is a premier outpatient psychiatry platform in the Southern U.S., specializing in comprehensive, interventional treatments for complex and treatment-resistant psychiatric conditions.

- The Company operates with a strong in-network payer base and has established itself as a trusted regional provider, with ~3,300 annual interventional treatments and 50+ referring providers.

Financial Highlights



Key Investment Highlights

- Early (2019) adopter of Spravato and J&J ATOM program participant, with a scaled REMS-certified program (~85–90 visits/week)
- 9 SPRAVATO® chairs with ~216 weekly treatment capacity at a **current utilization of ~40%**, substantial upside available
- Comprehensive, **one-stop outpatient model** spanning med management, psychotherapy, Spravato, TMS, Ketamine, HRT, labs, and on-site pharmacy
- **95% commercial/Medicare** with minimal self-pay, reflecting strong credentialing and reimbursement quality
- **Owned Brainsway TMS asset**, fully paid-off system with ~75% useful life remaining, dual coils and faster mapping
- **Stable, salaried multi-provider model** with experienced (3+ year tenure) clinicians operating under formal supervision protocols
- **Longer, psychotherapy-integrated visits** of 30 min drive higher reimbursement, stronger outcomes, and improved retention vs. standard 10–15 min check-ins

Transaction Overview

The owner is seeking a strategic or financial partner to support continued growth while maintaining clinical excellence. The seller is open to a transition period and has been working on shifting care delivery to associate providers demonstrating scalability and reduced reliance on the owner